Epigral targets ₹5,000 crore revenue by FY31 on capacity expansion
In short
Epigral said it wants to reach Rs 5,000 crore in revenue by 2030-31. The company expects about Rs 2,900 crore this financial year, after around Rs 2,500-2,530 crore in FY26, and says more capacity in CPVC Resin and ECH should help from next year.
This matters because investors will watch whether the factory expansion lifts sales as planned. The report does not say how much the new capacity will add or whether the target will be met.
What the reporting says
Epigral said it is targeting revenue of Rs 5,000 crore by 2030-31, driven by capacity scale-ups in CPVC Resin and Epichlorohydrin (ECH). The Business Standard summary says a senior executive expects about Rs 2,900 crore in revenue this fiscal year, after FY26 revenue of around Rs 2,500-2,530 crore. The immediate implication is that future growth depends on the planned production ramp-up, while the exact timing and execution remain uncertain.
Why it matters
Epigral outlined a revenue plan tied to production scale-ups in CPVC Resin and Epichlorohydrin, with management targeting Rs 5,000 crore by 2030-31. The summary also gives a near-term revenue view of about Rs 2,900 crore this fiscal year after FY26 revenue of roughly Rs 2,500-2,530 crore. The story points to capacity-led growth, but the execution details and contribution from each product are not stated.